AI × Pharma Consulting in France: A Confirmed Strategic Gap

The starting hypothesis

I mapped every player in France offering AI consulting for pharma. The result surprised me. Not because of what I found — but because of what I didn't find.

Across dozens of players analyzed — pharma strategy firms, generalist AI consultancies, freelancers, deeptech startups — none positions itself exclusively at this intersection. This gap is all the more striking when you consider that in the US, over 30 specialized players occupy this niche.

Pharma consultancies advise ON AI. They don't build it.

Analysis of major pharma consulting firms in France reveals a clear split: "advising ON AI" versus "advising WITH AI." Nearly all fall into the first category.

Only McKinsey/QuantumBlack and BCG X demonstrate real AI+pharma technical capability operated from Paris. McKinsey has a patented product, LifeSciences.AI, covering the full pharma value chain. BCG X/Gamma, whose AI Science Institute is based in Paris, developed FACET (an open-source library with Scikit-Learn) and collaborates with Merck on therapeutic target discovery via AI/GenAI.

Everyone else stays in classic strategy or regulatory consulting:

• Roland Berger publishes reports ("Pharma at the Intelligence Frontier") but has no internal technical capability
• PwC Strategy&, despite producing the LEEM 360° Barometer, has no AI technical offering of its own — AI skills sit in PwC Consulting, not Strategy&
• L.E.K. Consulting doesn't even mention AI on its Life Sciences page
• Cepton Strategies (now merged with Vintura/Cencora) hosts AI roundtables but has no technical capability

Accenture and Deloitte are an intermediate case: their global AI+pharma offerings are strong (Accenture leads the IDC MarketScape 2025, Deloitte developed CortexAI™), but in France their focus leans toward operational digital transformation rather than deep learning applied to pharma R&D.

Generalist AI firms touch pharma without mastering it

Among French data/AI consultancies, two stand out — but neither specializes in pharma.

Artefact is the most advanced: a dedicated Healthcare practice with 50+ specialized health consultants, a major client (Sanofi), an agentic AI solution for pharmacovigilance (PSUR/DSUR automation, 30% time reduction). Yet pharma remains one sector among many, and expertise concentrates on marketing and pharmacovigilance — not drug discovery or clinical trials.

Capgemini Invent deploys the most structured Life Sciences division: a "Clinical Trials Operation Center" (500+ clinical trials), "Intelligent Regulatory, Compliance and Quality" offering with GxP expertise. It's probably the most complete player in France for AI implementation in life sciences — but this is large-scale technology integration, not niche AI consulting.

Quinten Health deserves mention: an AI-in-health pioneer for 13 years with 500+ projects, specializing in real-world disease modeling, and its PharmIA branch for hospital pharmacists. With a €14M raise, it's the only French player approaching a dedicated AI+pharma positioning — but oriented toward real-world data rather than strategic AI consulting.

The rest — Ekimetrics (limited to pharma marketing mix), Sia Partners, Wavestone, Eleven Strategy, OCTO Technology — either have a shallow "health" sector page or no pharma vertical at all. Keyrus Life Science, historically strong in clinical data, was sold to Astek in June 2025, eliminating the only data-native CRO from a French AI group.

Freelancers at this intersection can be counted on one hand

The freelance platform search confirms the gap dramatically. Out of ~8,900 freelancers tagged "Artificial Intelligence" on Malt (France's largest freelance platform), only 5 to 8 also mention the pharmaceutical industry. Among them, the most relevant are data scientists with secondary pharma experience — not consultants positioned specifically at the AI+pharma intersection.

No micro-consultancy (2-20 people) explicitly positioned as "AI consulting for pharma/biotech" was identified in France.

The total number of freelancers truly positioned at the AI/ML + pharma intersection in France is estimated at 10-25 people, including those not visible online. No specialized "AI + health/pharma" consultant collective exists. Université Paris-Saclay offers a certificate in "Artificial intelligence in health, from drug to patient" (92 hours) — a sign that training is emerging, but the independent consultant pool is not yet structured.

French startups build products, never consulting

The French AI+pharma ecosystem is vibrant in technology startups, but none of them do consulting. The distinction is clear-cut:

• Owkin — agentic AI platform for drug discovery and clinical trials (federated learning, Sanofi/BMS/AstraZeneca clients, ~$300M estimated 2024 revenue)
• Aqemia — computational drug discovery (generative AI + quantum physics), proprietary pipeline, Sanofi ($140M), Servier, J&J collaborations. Funding >€100M
• Iktos — SaaS (Makya™, Spaya™) + professional services for Pfizer, Merck, Servier, Pierre Fabre. Servier deal potentially reaching €1B
• Qubit Pharmaceuticals, Volta Medical, Gleamer (acquired by RadNet for ~€230M), Implicity, Median Technologies — all exclusively product companies

These startups absorb PhD+AI+pharma talent internally rather than letting them become independent consultants. This talent siphoning partly explains the consulting gap.

In the US, an ecosystem 10x denser

The international comparison confirms that the French gap is not a research artifact but a real structural deficit.

ZS Associates dominates the segment with 13,000 employees, ~70% of revenue historically from pharma/biotech, and the rank of Everest Group 2025 Leader #1 in Life Sciences AI and Analytics Services. Its proprietary ZAIDYN® platform makes it a player with no equivalent in France — or even in Europe.

In the UK, Eularis (founded by Dr. Andrée Bates) is the reference for boutique 100% AI+pharma firms: 20+ years of expertise, 1,000+ AI strategies delivered, top 20 pharma clients. Players like Fast Data Science, PharmaTools.AI, and IntuitionLabs complete the ecosystem.

| Category | US/UK | France | |---|---|---| | Boutique 100% AI+pharma firms | Eularis, IntuitionLabs, PharmaTools.AI, ODAIA | None | | Large specialized pharma+analytics/AI | ZS (13,000), Beghou (250+), Axtria | No equivalent | | Data/AI firms with pharma vertical | Cognizant, Saama, etc. | Artefact, Capgemini Invent, Quinten | | Total players | 30-50+ | 5-10, with zero 100% pharma+AI |

A market under tension: strong demand, absent supply

The quantitative data reveals a French paradox. On one side, only 10% of French companies with 10+ employees used at least one AI technology in 2024 (INSEE). On the other, pharma+AI investments are surging:

• Sanofi: €300M invested in AI, 3 digital accelerators created since 2022
• Servier: major partnerships with Iktos and Owkin
• Pierre Fabre: experiments with Iktos (oncology drug discovery) and Artefact (e-retail)
• France 2030: €7.5B for health including €650M for digital health
• LEEM: 5,000 positions to fill by 2026 in digital health

The global AI pharma/biotech market reaches $6.63B in 2025. McKinsey estimates AI could generate $110B/year for the global pharmaceutical sector. Around 100 AI-designed drug candidates are in clinical evaluation.

The gap no one is filling

An early-stage biotech isn't going to hire a senior data scientist at €90K/year for a one-off need. They need someone who sits beside them for 3 weeks or 3 months, understands their pipeline, and delivers a result.

This gap is explained by five converging factors:

1. PhD+AI+pharma talent is siphoned by product startups or internal R&D departments
2. Generalist AI firms haven't invested in deep pharma domain expertise (pharmacokinetics, QSAR, EMA/ANSM regulatory)
3. Classic pharma consultancies haven't developed internal AI technical capabilities
4. The French pharma market is more concentrated than the US (a few large labs vs. thousands of biotechs)
5. AI maturity in French companies remains below the European average

This is exactly the niche I fill with SG AI Solutions. PhD in Neuroscience. Doctor of Pharmacy. Master's in Computer Science. 12 years analyzing neurophysiological signals for the pharmaceutical industry. Production code, not slide decks.

The existence of thriving players in this niche in the US/UK — ZS, Eularis, Beghou — proves the business model is viable. In France, the field is wide open.

If you're a biotech, a lab, or a pharma SME looking for someone who speaks Python and pharmacokinetics in the same sentence — book a discovery call to talk about it.